Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
CEO Schreiber to discuss changes made possible via proprietary virtual care platforms
LifeMD, a leading telehealth company (NASDAQ: LFMD), announced that CEO Justin Schreiber will participate in a panel at the LifeSci Partners Corporate Access Event, happening virtually from January 5-7, 2022. Schreiber will discuss how LifeMD's virtual care technology is transforming healthcare to improve affordability and patient outcomes. The panel, titled 'Telehealth & Digital Medicine: At a Crossroads of Virtual Care,' is scheduled for January 6 at 8:30 am ET. Interested parties can register for the webcast to view the discussion.
On December 23, 2021, LifeMD announced a cash dividend of $0.622483 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP), payable on January 14, 2022. The dividend will be distributed to shareholders of record on January 4, 2022. LifeMD is a growing telehealth company providing virtual medical care across the U.S., emphasizing affordable treatment and home delivery of prescriptions.
LifeMD (NASDAQ: LFMD) will present at the Stephens Annual Investment Conference on November 29, 2021, at 9:00 AM CT / 10:00 AM ET. Management will also conduct one-on-one meetings at the event.
The conference will take place in Nashville, and details for accessing the presentation will be available via a webcast link. Interested investors can find additional information on the company's website. LifeMD is a rapidly growing telehealth company providing direct-to-patient medical care across all 50 states.
LifeMD, Inc. (NASDAQ: LFMD) reported a record revenue of $24.9 million for Q3 2021, showing a 127% increase year-over-year. The company attributes 93% of its revenue to subscriptions, up from 61% last year. Adjusted EBITDA loss improved 24% sequentially, reaching $(9.0 million), indicating ongoing enhancements in profitability. Telehealth order volume surged 153%, totaling 232,293 orders. After a recent stock offering, LifeMD is in a strong capital position to pursue further growth and aims for Adjusted EBITDA break-even by Q4 2022.
LifeMD, a telehealth company, launched its virtual care platform on November 8, 2021, aiming to provide 24/7 access to personalized healthcare across the US. The platform offers direct communication with in-house physicians, unlimited messaging, and discounted prescriptions. Initially available via invitation, public access will begin on January 1, 2022. LifeMD emphasizes addressing the shortage of primary care physicians in America, aiming to enhance healthcare accessibility and efficiency.
LifeMD, a fast-growing telehealth company, announced its participation in the Credit Suisse Virtual Annual Healthcare Conference from November 8-11, 2021. The company will present on November 11 at 10:30 am ET, providing insights into its operational strategies and growth. Investors can register for the event online. LifeMD offers cash-pay virtual medical care across all U.S. states, focusing on accessible healthcare solutions. A replay of the presentation will be available in the investor relations section of the company's website.
LifeMD, Inc. (NASDAQ: LFMD) will host a conference call on November 10, 2021, at 5:00 p.m. ET to discuss its financial results for the third quarter of fiscal 2021. The call will follow a press release with results issued beforehand. The telehealth company provides virtual medical treatments and prescription medications across the U.S. interested parties can join the call by dialing 1-877-705-6003 in the U.S. and find additional information on the company's website.
LifeMD, Inc. (NASDAQ: LFMD) has successfully closed an underwritten public offering of 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, with a total liquidation preference of $35 million. After offering costs, the net proceeds are estimated at $32.9 million. The funds will be allocated towards a segregated dividend account, repaying debt (approximately $10 million), and for general corporate purposes, including customer acquisition. The offering included a 30-day underwriter option for an additional 210,000 shares.
LifeMD, Inc. (NASDAQ: LFMD) has successfully closed its underwritten registered public offering of 3,833,334 shares of common stock, raising approximately $21.4 million. The offering included 500,000 shares from the underwriter’s option to purchase additional shares. The proceeds will be utilized for repaying existing indebtedness and for working capital, including patient customer acquisition and capital expenditures. B. Riley Securities acted as the sole book-running manager for this offering, which was made under an effective shelf registration statement.
LifeMD, Inc. (NASDAQ: LFMD) announced the pricing of its underwritten public offering of 1,400,000 shares of 8.875% Series A Cumulative Perpetual Preferred Stock, totaling $35 million in liquidation preference. The offering, with a 30-day option for underwriters to purchase an additional 210,000 shares, is set to close on October 4, 2021. Proceeds will fund a segregated dividend account, repay certain debts, and cover working capital, including new patient acquisition expenses. The offering is made under an effective shelf registration statement with the SEC.
FAQ
What is the current stock price of Lifemd (LFMD)?
What is the market cap of Lifemd (LFMD)?
